Intravenously administered 2'-deoxycytidine suppresses mouse myeloma tumor growth.
Biol Pharm Bull
; 35(2): 251-5, 2012.
Article
em En
| MEDLINE
| ID: mdl-22293357
ABSTRACT
We examined the in vivo effects of intravenously administered 2'-deoxycytidine (dCyd) on tumor growth and survival time in mice bearing SP2/0-Ag14 (SP2/0) myeloma tumors. Administration of dCyd tended to decrease the tumor volume and significantly decreased the tumor weight. A single intravenous administration of dCyd significantly increased survival time of the tumor-bearing mice. The effect of dCyd on tumor growth was maintained for at least 1 week after the final administration. The net amount of dCyd in the kidney, liver, and spleen of the tumor-bearing mice increased 2.5 to 5.3 fold compared with the amount in non-tumor-bearing mice. Our results suggest that the increase in dCyd in the mice inoculated SP2/0 myeloma cells plays an important role for the growth suppression of the tumor.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Desoxicitidina
/
Mieloma Múltiplo
/
Antineoplásicos
Limite:
Animals
Idioma:
En
Revista:
Biol Pharm Bull
Ano de publicação:
2012
Tipo de documento:
Article